Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting now

Conditions studied: Cytomegalovirus Infection, Hematopoietic Stem Cells Transplantation

In brief

This observational retrospective analysis will provide useful information for clinicians and payers, and local guidelines committee members, to improve the understanding of Cytomegalovirus clinical and economic burden and clinical management of pediatric patients undergoing allogeneic Hematopoietic Stem Cells Transplantation in Italy.

Key facts

Study ID

NCT06916195

Run by

MSD Italia S.r.l.

People needed

230

Starts

2025-05-09

Expected to finish

2026-07-15

Last updated by the study team

2026-04-06

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients from birth to less than 18 years of age (at the moment of the allogeneic HSCT);
• Patients who received allogeneic HSCT between January 2018 and June 2020;
• Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF), if applicable.

You may not qualify if…

• Letermovir use at any time

Where it is running

• IRCCS Istituto Giannina Gaslini, Trapianto di Cellule Staminali Emopoietiche, Dipartimento di Onco-Ematologia Pediatrica — Genova, Italy (enrolling)
• Ospedale San Gerardo, Clinica Pediatrica — Monza, Italy (enrolling)
• IRCCS Ospedale Pediatrico Bambino Gesù, Dipartimento di Pediatria Ematologia e Oncologia — Roma, Italy (enrolling)
• Ospedale Infantile Regina Margherita, Dipartimento Patologia e Cura del Bambino — Torino, Italy (enrolling)
• Azienda Ospedale-Università di Padova, Clinica di Oncoematologia Pediatrica — Padova, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.